Top

Published in:

01-06-1997

Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice

Authors: Lisa Polin, Frederick Valeriote, Kathryn White, Chiab Panchapor, Susan Pugh, Juiwanna Knight, Patricia LoRusso, Maha Hussain, Elaine Liversidge, Nancy Peltier, Trimurtulu Golakoti, Gregory Patterson, Richard Moore, Thomas H. Corbett

Published in: Investigational New Drugs | Issue 2/1997

Title: Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice
Authors: Lisa Polin
Frederick Valeriote
Kathryn White
Chiab Panchapor
Susan Pugh
Juiwanna Knight
Patricia LoRusso
Maha Hussain
Elaine Liversidge
Nancy Peltier
Trimurtulu Golakoti
Gregory Patterson
Richard Moore
Thomas H. Corbett
Publication date: 01-06-1997
Publisher: Kluwer Academic Publishers
Published in: Investigational New Drugs / Issue 2/1997
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1023/A:1005856605726

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 2/1997

A phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer, a southwest oncology group study

Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer

Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder

Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels

An ECOG Phase II Study of Amonafide in Unresectable or Recurrent Carcinoma of the Head and Neck (PB390)

Phase I trial of fluorouracil modulation by n-phosphonacetyl-l-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer